21 results about "Postmenopausal osteoporosis" patented technology

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

The invention provides an application of miR-337 in preparation of a medicine for treating osteoporosis, which is used for the medicine for treating osteoporosis, and relates to the technical field of biomedicine. The research of the inventor finds that miR-337 can activate p53 to promote apoptosis of osteoclasts, has a certain treatment effect on osteoporosis, and can be used for preparing the medicine for treating osteoporosis; the nano vesicles derived from human umbilical cord mesenchymal stem cells have certain anti-inflammatory activity and have a positive effect on treatment of osteoporosis. According to the application disclosed by the invention, miR-337 is further loaded on nano vesicles derived from human umbilical cord mesenchymal stem cells, and the research of the inventor finds that the medicine has a good treatment effect on osteoporosis, provides a new strategy for preventing postmenopausal osteoporosis, and has remarkable clinical transformation potential.

The invention discloses a telmisartan glucoside derivative, a microbial conversion preparation method thereof and application of the telmisartan glucoside derivative in preparation of a medicine for preventing or treating osteoporosis. The telmisartan glucoside derivative is characterized in that a telmisartan propyl side chain is connected with a glucosyl group. According to the invention, a microbial conversion technology is utilized, telmisartan is taken as a substrate, and glucosyl is introduced into a telmisartan propyl side chain in a regioselective manner, so that the telmisartan glucoside derivative with a novel structure is obtained. Experiments on the osteoblast proliferation promoting activity and the postmenopausal osteoporosis resisting effect of the telmisartan glucoside derivative by using an in-vitro osteoblast model and an ovariectomized induced osteoporosis mouse model prove that the telmisartan glucoside derivative has relatively good osteoblast proliferation promoting activity and postmenopausal osteoporosis resisting activity; the compound can be used as an active component of a medicine for treating osteoporosis, and has wide application.

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

This invention discloses the application of an inhibitor of transcription factor C / EBPβ in the preparation of a drug for treating postmenopausal osteoporosis. This invention also discloses the application of transcription factor C / EBPβ in screening drugs that reduce postmenopausal FSH levels, wherein the drugs inhibit the expression of transcription factor C / EBPβ. Furthermore, this invention discloses the application of compounds #11a and CF3CN in the preparation of a drug for treating postmenopausal osteoporosis. This invention reveals for the first time that the C / EBPβ-AEP pathway participates in promoting FSHβ synthesis in a menopausal model. By reducing the transcription factor activity of C / EBPβ, it can reduce FSH expression at the pituitary gland, promote osteogenic differentiation, inhibit osteoclast resorption, and effectively alleviate PMOP symptoms. Compounds #11a and CF3CN can effectively achieve both anti-bone resorption and bone formation-promoting functions, achieving coupled treatment of PMOP.

The invention relates to the technical field of health risk assessment, in particular to a postmenopausal osteoporosis risk prediction and traditional Chinese and western medicine intervention management system. The system quantifies the trend risk of the bone mineral density through the deviation change of the bone mineral density risk value in time sequence, and combines the initial bone mineral density risk to divide the group and analyze and identify the risk degree of the group; coupling the drop fluctuation characteristics of hormones with the change of bone metabolism markers to obtain the comprehensive metabolic risk influence degree; determining the comprehensive influence degree of osteoporosis by utilizing the group comprehensive bone mineral density risk degree dynamic adjustment and combining the external risk influence degree and the comprehensive metabolic risk influence degree; and based on the osteoporosis comprehensive influence degree of the sample data, training a neural network model to carry out risk prediction. According to the method, the risk model is constructed by considering the multi-dimensional influence of hormone metabolism and behavioral habits of the postmenopausal patient and the multi-dimensional coupling evaluation value, so that the risk prediction accuracy is improved, and more comprehensive and reliable data support is provided for bone health management of postmenopausal women.

This invention provides the application of Neoruscogenin in the preparation of anti-osteoporosis drugs, belonging to the field of pharmaceutical biotechnology. It was found that Neoruscogenin can significantly increase bone volume fraction, bone surface area to tissue volume ratio, bone mineral density, trabecular bone number, and trabecular bone thickness in osteoporotic mice, while significantly reducing trabecular bone separation; that is, Neoruscogenin can alleviate low bone mass in postmenopausal osteoporotic mice. Furthermore, Neoruscogenin treatment for 8 weeks did not significantly affect the major organs of mice, suggesting the biocompatibility of Neoruscogenin.

The present application relates to the application of Radix Rehmanniae Preparata polysaccharide in postmenopausal osteoporosis, and relates to the application of active ingredients of traditional Chinese medicine in the treatment of bone metabolism diseases. The Radix Rehmanniae Preparata polysaccharide can improve the postmenopausal osteoporosis by up-regulating the expression of estrogen receptors and promoting the synthesis of estrogen.

This invention provides an application of the PDK4 gene, which is used to prepare drugs to improve postmenopausal osteoporosis. PDK4 gene deletion in bone marrow mesenchymal stem cells (BMSCs) reduces their osteogenic differentiation capacity and inhibits mitochondrial division by blocking the E2-DRP1 signaling axis. Overexpression in bone tissue reverses bone formation inhibition caused by postmenopausal osteoporosis. This invention redefines the biological function of the PDK4 gene in the skeletal system. This gene promotes osteogenic differentiation of BMSCs through the E2-ERα-PDK4-MYH9-DRP1 signaling axis, thus improving postmenopausal osteoporosis and providing a new theoretical framework and potential target for developing bone-promoting therapies for postmenopausal osteoporosis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a kidney-tonifying and liver-nourishing compound preparation in preparation of a medicine for improving postmenopausal osteoporosis, and the kidney-tonifying and liver-nourishing compound preparation comprises the following components in parts by weight: 5-15 parts of roasted herba epimedii, 5-15 parts of fructus cnidii, 50-70 parts of roasted astragalus membranaceus and 10-30 parts of dogwood. Experiments show that the kidney-tonifying and liver-nourishing compound preparation can improve the problems of gap enlargement and structure looseness of bone tissue morphology and can inhibit bone loss, namely, the kidney-tonifying and liver-nourishing compound preparation has the effect of improving postmenopausal osteoporosis; compared with a traditional estrogen replacement therapy, the kidney-tonifying and liver-nourishing compound preparation has the advantages that the side effects are obviously reduced, the safety is improved, and a foundation is laid for developing safe and effective anti-osteoporosis medicines in the future.

The application discloses application of a medicine, miltefosine, in promoting bone formation and preventing and treating osteoporosis. In the bone formation process, the expression of protein phosphatase PPM1A in osteoblasts is significantly increased, the dephosphorylation of a core protein Smad2 of a TGF-beta signal path is regulated, the TGF-beta signal path is inhibited, the expression of an osteogenic marker is promoted, and the osteogenic ability of the organism is enhanced. The application discloses that the medicine, miltefosine, is used as a PPM1A enzyme activity catalyst, the in-vivo intervention of the medicine can significantly accelerate bone repair and delay bone loss of postmenopausal osteoporosis, a mechanism is that the enzyme activity of PPM1A of osteoblasts is catalyzed, the dephosphorylation of Smad2 protein is promoted, the TGF-beta / Smad2 signal path activity is inhibited, bone formation is promoted, bone repair is accelerated, and bone loss is prevented. Therefore, the miltefosine has a good application prospect in clinical treatment of promoting osteogenesis and preventing and treating osteoporosis.

The invention belongs to the technical field of medicine research and development, and provides application of edaravone in preparation of a medicine for treating postmenopausal osteoporosis aiming at the technical problem that whether edaravone has a treatment effect on postmenopausal osteoporosis or not is not reported at present. In addition, by constructing a mouse ovariectomized model and combining with a ferroptosis-induced osteogenesis / osteoclast system, the edaravone is proved to be capable of effectively increasing calcium salt deposition and mineralization after osteoporosis, improving poor osteogenesis of osteoblasts and osteoblast inflammatory response caused by osteoporosis, effectively improving FSP1 expression and improving osteoporosis. And meanwhile, the expression of 5-LOX and ACSL4 proteins is reduced, and the intraosseous ferroptosis microenvironment of the postmenopausal osteoporosis is regulated through ways of inhibiting ROS, inhibiting lipid peroxidation and the like, so that the treatment effect of relieving the progress of the postmenopausal osteoporosis is achieved.

The present application relates to the technical field of health risk assessment, in particular to a postmenopausal osteoporosis risk prediction and traditional Chinese and western medicine intervention management system. The system quantifies the trend risk of bone mineral density by the deviation change of bone mineral density risk value in time sequence, combines with the initial detection of bone mineral density risk to divide groups and analyze and identify the group risk degree; the comprehensive metabolic risk influence degree is obtained by coupling the hormone drop fluctuation characteristics with the bone metabolism marker change; the osteoporosis comprehensive influence degree is determined by using the group comprehensive bone mineral density risk degree dynamic adjustment, combining with the external risk influence degree and the comprehensive metabolic risk influence degree; and the neural network model is trained based on the osteoporosis comprehensive influence degree of sample data to predict the risk. The present application considers the multidimensional influence of postmenopausal patient's internal hormone metabolism and behavior habit, constructs the risk model by multidimensional coupling evaluation value, improves the risk prediction accuracy, and provides more comprehensive and reliable data support for the bone health management of postmenopausal women.

The application discloses application of hsa-miR-144-5p as a postmenopausal osteoporosis diagnosis marker. The application adopts high-throughput gene chip technology to detect serum miRNA expression profiles of PMOP patients, and compares with postmenopausal non-osteoporosis population, screens differential expression miRNAs between the two, further verifies the differential level of the selected miRNA between the PMOP patients and n-PMOP through real-time fluorescent quantitative PCR technology, confirms the clinical application value of the screened marker, and finally provides a simple and easy, high-precision biomarker for clinical PMOP diagnosis.

The present application relates to a kind of protein markers for diagnosing postmenopausal osteoporosis and its application, belong to biological medicine technical field.The present application is screened, and it is found that NADH dehydrogenase 1 beta subcomplex subunit 4, NADH dehydrogenase 1 beta subcomplex subunit 5, NADH dehydrogenase 1 beta subcomplex subunit 6, NADH dehydrogenase 1, NADH dehydrogenase 1 alpha subcomplex subunit 8, cytochrome c oxidase subunit 7C, cytochrome c oxidase subunit 5A and cytochrome c oxidase subunit 7A2 can be used alone or in combination in the diagnosis test of postmenopausal osteoporosis, to accurately evaluate the PMOP state of subject.Further, the combination of NDUB5 and NDUA8 two protein markers shows excellent diagnostic sensitivity and specificity, which is helpful for early diagnosis of PMOP, screening of high-risk population of fracture and precise prevention and treatment.

The invention relates to a protein marker for diagnosing postmenopausal osteoporosis and application thereof, and belongs to the technical field of biological medicine. Through screening, an NADH dehydrogenase 1 beta sub-complex subunit 4, an NADH dehydrogenase 1 beta sub-complex subunit 5, an NADH dehydrogenase 1 beta sub-complex subunit 6, an NADH dehydrogenase 1, an NADH dehydrogenase 1 alpha sub-complex subunit 8, a cytochrome c oxidase subunit 7C, a cytochrome c oxidase subunit 5A and a cytochrome c oxidase subunit 7A2 are found. The kit can be used in a diagnostic test of postmenopausal osteoporosis independently or in a combined manner, so as to accurately evaluate the PMOP state of a subject. Furthermore, the combination of the two protein markers NDUB5 and NDUA8 shows excellent diagnosis sensitivity and specificity, and is beneficial to early diagnosis of PMOP and screening and precise prevention and treatment of high-risk groups of fracture.

The application discloses application of a lignan and flaxseed polysaccharide in preparation of health care products for improving osteoporosis, and belongs to the technical field of health care functions. The postmenopausal osteoporosis model is established by ovariectomized rats, and the comparison of the lignan and flaxseed polysaccharide on bone metabolism, related bone conversion indexes, bone microstructure, bone biomechanics and intestinal flora of the rats is systematically studied, so that the dominant material for improving osteoporosis of the lignan and flaxseed polysaccharide is explored, and a more effective theoretical basis is provided for development of functional food of flaxseed.

This invention discloses the use of donkey-hide gelatin in the preparation of products for treating postmenopausal osteoporosis, belonging to the field of new pharmaceutical applications of donkey-hide gelatin. The use of donkey-hide gelatin in the preparation of products for treating postmenopausal osteoporosis utilizes a mechanism of action that regulates immune cells to mediate bone immune balance, thus treating osteoporosis. This invention reveals for the first time a novel mechanism by which donkey-hide gelatin regulates immune cells to mediate bone immune balance. This mechanism endows traditional donkey-hide gelatin with entirely new pharmaceutical value, exceeding expectations based on its traditional description as "strengthening muscles and bones." It indicates that donkey-hide gelatin can be used to prepare drugs or health products for treating postmenopausal osteoporosis, and is particularly suitable for the development of anti-osteoporosis preparations based on immune modulation mechanisms.

This invention relates to the field of medical data processing technology, specifically to a diagnostic method for postmenopausal osteoporosis (PMOP) based on oral salivary bacteria. The method includes: collecting saliva samples from the subject in the morning on an empty stomach and labeling the subject's menopausal years; obtaining the relative abundance of Lactobacillus and Streptococcus, the concentrations of propionic acid and acetic acid, and the pH value; determining the corrected bone mineral density (BMD) correlation value using a diagnostic model; and outputting suggestions based on the BMD correlation value. This invention utilizes the principle that the decline in estrogen levels in postmenopausal women leads to an imbalance in the salivary flora, with an increase in acid-producing bacteria leading to increased acetic acid secretion and a decrease in alkali-producing bacteria leading to decreased propionic acid secretion. These two factors synergistically exacerbate osteogenic inhibition and increased bone resorption. Furthermore, since most saliva is partially absorbed after swallowing, the long-term accumulation of propionic acid and acetic acid can interfere with bone metabolism through the circulatory system, thus providing a preliminary diagnosis of PMOP. By collecting only saliva samples, without blood collection or radiation, the procedure is simple, painless, and provides physicians with preliminary diagnostic suggestions.

Provided is use of an inhibitor of transcription factor C / EBPβ in preparing a medicament for treating postmenopausal osteoporosis (PMOP). Specifically, provided is use of compound # 11a and CF3CN in preparing a medicament for treating PMOP. The C / EBPβ-AEP pathway is involved in promoting the synthesis of FSHβ in menopausal models. By reducing the transcription factor activity of C / EBPβ, the expression of FSH in the pituitary can be reduced, thereby promoting osteogenic differentiation, inhibiting osteoclastic resorption, and effectively alleviating the symptoms of PMOP. Compounds # 11a and CF3CN can effectively achieve the dual functions of anti-bone resorption and osteogenesis promotion, thereby achieving a coupled therapeutic effect for PMOP.